India, July 2 -- Ahmedabad-based Cadila Pharmaceuticals has announced the launch ofBilacad Dex Syrup, to address the increasing burden of respiratory and allergy-related conditions with a novel fixed-dose combination ofBilastine, Dextromethorphan, and Phenylephrine.

Bilacad Dex Syrupis specifically formulated to target multiple symptoms associated with the common cold and allergic rhinitis, including cough, nasal congestion, and allergic manifestations such as sneezing and itching. Its three active pharmaceutical ingredients work in synergy to deliver rapid and sustained relief:

Bilacad Dex Syruprepresents Cadila Pharmaceuticals' strategic expansion into combination therapies that cater to the evolving needs of patients and prescribers ...